Impact of insulin resistance on therapeutic response to oral treatment of chronic hepatitis C virus infection

Magda S. Hassan, Soha Saoud Abd El Monem, Ahmad F. Hasanain, Rasha Hosny Sayed, Amal Abdel aziz


Background& aim: HCV infection is one of the major health problems in our country. Prevalence of DM is higher among patients with chronic HCV infection. Insulin resistance (IR) is common in such and its impact on sustained virological response (SVR) is not well studied. This work was designed to assess impact of IR on SVR.Patients & methods: Between July 2016 and June 2017; 200 patients with chronic HCV infection were enrolled in a prospective study. Exclusion criteria included decompensated cirrhosis, hepatocellular carcinoma or extrahepatic malignancy, co-infection with HBV or HIV infection. HOMA and IR were assessed at baseline of therapy and 3-months post-therapy.   Patients received sofosbuvir and daclatasvir for 3 months (chronic hepatitis) and for 6 months in (liver cirrhosis).Results: Mean age of patients was 49.89 ± 9.01 years, 111 (55.5%) patients were male and 180 (90%) achieved SVR. Baseline IR had insignificant difference between responders and non-responders (93% v. 90%; P= 0.45), while baseline HOMA was significantly higher in non-responders (10.11 ± 3.03 vs. 8.48 ± 2.98; P= 0.01). Also, post-therapy IR had insignificant difference between both groups (73.3% vs. 85%; P= 0.05), while post-therapy HOMA was significantly higher in non-responders (7.12 ± 2.31 vs. 5.06 ± 1.34; P= 0.01). Predictors of non-responders were age (> 40 years), low serum albumin and post-therapy IR.Conclusion: Baseline IR had no impact on SVR but it showed significant improvement in presence of SVR.


insulin resistance; homeostatic model assessment; sustained virological response


Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R: Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Journal of Hepatology, 2013; 57: 2164-2170. doi: 10.1002/hep.26218. Epub 2013 May 6.

Mohd Hanafah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of agespecifc antibody to HCV seroprevalence. Journal of Hepatology, 2013; 57: 1333-1342. doi: 10.1002/hep.26141. Epub 2013 Feb 4.

Elhelbawy M, Abdel-Razek W, Alsebaey A, Hashim M, Elshenawy H, Waked I. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. European Journal of Gastroenterology & Hepatology, 2019; 31(1):16-23. doi: 10.1097/MEG.0000000000001215.

Lecube A, Hernandez C, Genesca J, Simo R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care2006; 29:1140–1149.DOI:10.2337/diacare.2951140. PMID:16644655

Tsochatzis EA, Bosch J, Burroughs AK. Live cirrhosis.Lancet, 2014; 383:1749–1761. doi: 10.1016/S0140-6736(14)60121-5. Epub 2014 Jan 28.

Elkarmouty K, Ramadan K, Ghanem H: Chronic hepatitis C virus infection as a risk factor for non-insulin dependent diabetes mellitus. Egyptian Journal of Biochemistry and Molecular Biology, 2002; 5:121-137.

De Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol, 2010; 53:762–768.

Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab, 2008;294:15–26. Epub 2007 Oct 23.

European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. J Hepatol 2017; 66:153–194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22.

Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World journal of gastroenterology, 2018. Oct 14;24(38):4330. doi: 10.3748/wjg.v24.i38.4330.

Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y: Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol. Lausanne, 2015, 14(6):134. doi: 10.3389/fendo.2015.00134. eCollection 2015.

Mousa OY, Kim CH, Pham LE, Zela SA, Egwim CI, Sey VA. (2017): Predictors of Sustained Virologic Response and Failure of First DAA Therapy in Chronic Hepatitis C Patients. SM J Hepat Res Treat. 2017; 3(1): 1014.doi: 10.36876/smjhrt.1014

Snyder HS, Ali B, Gonzalez HC, Nair S, Satapathy SK. Efficacy and Safety of Sofosbuvir-Based Direct Acting Antivirals for Hepatitis C in Septuagenarians and Octogenarians.. Journal of clinical and experimental Hepatology, 2017; 7(2): 93–96. DOI: 10.1016/j.jceh.2017.03.009. PMID: 28663671. PMCID: PMC5478933

Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WT, MacDonald DC: Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 2016; 64: 1224–1231. doi: 10.1016/j.jhep.2016.01.029. Epub 2016 Jan 30.

Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K, Goto H. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data. J Gastroenterol Hepatol, 2017. Nov; 32(11), 1879–1886.

Butt AA, Yan P, Aslam S, Shaikh OS, Abou-Samra AB. Incient diabtes and glucose control after HCV treatment with DAAs in ERCHIVE. Conference on Retroviruses and Opportunistic Infections, Boston, abstract 88. 2019.

Saad Y, Ahmed A, Doa’a AS, Doss W: Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4. Eur. J. Gastroenterol. Hepatol, 2013, 25:920-925. doi: 10.1097/MEG.0b013e32835f2726.

Pavone P, Tieghi T, d'Ettorre G, Lichtner M, Marocco R, Mezzaroma I, Passavanti G, Vittozzi P, Mastroianni CM, Vullo V. Rapid decline of fasting glucose in HCV diabetic patients treated with directacting antiviral agents. Clin. Microbiol. Infect, 2016; 22:462-468. doi: 10.1016/j.cmi.2015.12.030. Epub 2016 Jan 23.

Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, Chang M, Ioannou GN: Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Diabetes Care, 2017; 40:1173– 1180. doi: 10.2337/dc17-0485. Epub 2017 Jun 28.

Sersté T, Nkuize M, Moucari R, Van Gossum M, Reynders M, Scheen R, Vertongen F, Buset M, Mulkay JP, Marcellin P. Metabolic disorders associated with chronic, hepatitis C: impact of genotype and ethnicity. Liver Int, 2010, 30:1131-1136.

Li J, Zhang T, Gordon SC, Rupp LB, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Schmidt MA: Impact of sustained virological response on incidence of type 2 diabetes in hepatitis C patients. Hepatology, 2017; 66:531A.

doi: 10.1111/jvh.12887. PMCID: PMC6205163.

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.